Advanced Search

 

Study ID Status Title Patient Level Data
MAD103894 Completed A 28 day, Polysomnographic and Subjective Assessment of GW679769 for the Treatment of Primary Insomnia: A Randomized, Double-blind, Parallel-Group, Placebo-Controlled Trial.
MAD105514 Completed A randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of GW679769 on polysomnographic sleep recordings, subjective sleep assessment, and daytime cognitive function in elderly and non-elderly subjects with primary insomnia
MAD105516 Completed A randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of morning administration of GW679769 (10mg and 30 mg) on polysomnograph sleep recordings, subjective sleep assessment, daytime cognition and psychomotor function in subjects with primary insomnia
MAG103114 Completed A single-blind, single dose, placebo controlled, first time in human study to assess the safety, tolerability and pharmacokinetics of ascending doses of GSK249320 in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
MD7108240 Completed A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib drops, administered for 28 days to adult subjects with neovascular age-related macular degeneration.
MD7110861 Completed An open-label, two-period, fixed-sequence study in Healthy volunteers to evaluate the effects of repeat oral dosing of ketoconazole on the pharmacokinetics of a single dose of pazopanib (GW786034) administered as eye drops
MD7111396 Completed An extension study to protocol MD7108240: pazopanib eye drops in subjects with neovascular age-related macular degeneration
MEK111054 Completed An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects with Solid Tumors or Lymphoma
MET111516 Completed An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of two forms ofGSK1363089 in Subjects with Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MET111643 Completed A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects with Metastatic Gastric Cancer Study Listed on ClinicalStudyDataRequest.com
MET111644 Completed A Phase II Study of the c-MET RTK Inhibitor XL880 in Subjects with Papillary Renal-Cell Carcinoma Study Listed on ClinicalStudyDataRequest.com
MET111646 Completed A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Study Listed on ClinicalStudyDataRequest.com
MET111647 Completed A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MET111648 Completed A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects with Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MKI102428 Completed A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD) Study Listed on ClinicalStudyDataRequest.com
MKI106209 Completed A randomised, double-blind, placebo-controlled parallel study to assess the safety, tolerability,pharmacodynamics and steady state pharmacokinetics of repeated doses of GW856553 in patients with COPD
MOT107043 Completed A First-Time-in-Human Randomized Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of the Oral Motilin Receptor Agonist GSK962040, in Male and Female Healthy Subjects Study Listed on ClinicalStudyDataRequest.com
MOT109681 Completed A randomized, double-blind, ascending dose trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, of repeat doses of motilin receptor agonist GSK962040 in male and female healthy volunteers Study Listed on ClinicalStudyDataRequest.com
MT400-101 (112490) Completed A study to evaluate the bioavailability of combo formulation, each of its components and currently marketed versions of the components in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
MT400-102 (112491) Completed A study to evaluate the effect of food on the bioavailability of a sumatriptan succinate and naproxen sodium combination tablet in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
MT400-103 (112492) Completed A study to evaluate the bioavailability of different dose combinations of sumatriptan succinate and naproxen sodium 500 mg in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
MT400-104 (112493) Completed An open-label study to investigate the effect of migraine attacks on the pharmacokinetics of a single dose of Treximet™ (formerly known as Trexima™) administered both during and outside of a migraine attack Study Listed on ClinicalStudyDataRequest.com
MT400-105 (112494) Completed A study to evaluate the pharmacokinetics and tolerability of two single Treximet™ (formerly known as Trexima™) tablets (administered two hours apart) in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
NAI30008 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study To Investigate The Efficacy And Safety Of Zanamivir (GG167) 10mg Administered Twice A Day For Five Days In The Treatment Of Influenza In Patients 12 Years Or Over With Asthma Or Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
NAI30009 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered by inhalation twice daily for five days in the treatment of symptomatic influenza A and B viral infections in children ages 5-12. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.